United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

sCD30 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:Lymphoid activation antigen CD30, Ki-1 antigen
  • Species:Human
Cat. No. Size Price


RAF091R 96 wells (1 kit) $721,83
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma, Cell culture supernatant

Sample Requirements

25 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store kit reagents between 2–8°C except controls. Store lyophilized controls at -20°C.

Calibration Curve

Calibration Range

1.6–100 ng/ml

Limit of Detection

0.3 ng/ml

Intra-assay (Within-Run)

CV = 4.1%

Inter-assay (Run-to-Run)

CV = 5.6%

Spiking Recovery

104,00%

Dilution Linearity

99,00%

Summary

Research topic

Cell surface proteins (sCD), Oncology

Summary

The CD30 (Ki-1) molecule was identified by a monoclonal antibody which was originally found to react with an epitop present in Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. Later, the Ki-1 antigen was found to be consistently expressed by a subgroup of diffuse largecell lymphomas that were called Ki-1 positive (Ki-1+) anaplastic large-cell lymphomas (ALCL). Characterization of the CD30 antigen has shown it to be in its mature form a transmembrane protein of about 120 kDa elaborated from an 84 kDa cytoplasmic precursor primarily through glycosylation. The cloning of the CD30 gene has allowed the identification of a cDNA with an open reading frame predicting a 595 amino acid polypeptide. The extracellular domain of CD30, comprising 365 residues, has proved to be homologous to that of the TNF-receptor superfamily. The CD30 gene is localized at chromosome 1q36, closely linked to other members of the TNF receptor superfamily comprising TNF-receptors, nerve growth factor, CD40, APO-1/Fas, CD27, OX40 and the neurotrophin receptor. The CD30 ligand (CD30L) has been identified, showing significant homology to TNFa, TNFb, FasL, CD40L, CD27L and
4-1BBl. CD30L is expressed on activated T-cells. Interactions of the cytokine receptor CD30 with its ligand induces pleiotropic biologic effects, such as differentiation, activation, proliferation and cell death. In CD30+ ALCL cell lines binding of CD30L induces apoptotic cell death. CD30 furthermore seems to be involved in the control of the CD40/CD40L signal, T-cell proliferation and B-cell maturation induced by T-cell cytokines. Thus, CD30 seems to transmit information that is essential for the immune response.
CD30 expression is strictly dependent on activation and proliferation of T- and B-cells. In pathological conditions, CD30 positivity is regarded as a peculiar attribute of Hodgkin's and Reed-Sternberg cells.
There is growing evidence for a potential role of the CD30 molecule in clinical use and therapy. An 85 kDa soluble form of the CD30 molecule (sCD30) has been shown to be released by CD30+ cell in vitro and in vivo.
It is probably derived from the 120 kDa membrane bound molecule by proteolytic cleavage. Serum sCD30 detection can be regarded as a marker of the amount of CD30+ cells present in the body.

Product References (3)

References

  • Mai K, Boldt A, Hau HM, Kirschfink M, Schiekofer S, Keller F, Beige J, Giannis A, Sack U, Rasche FM. Immunological Alterations due to Hemodialysis Might Interfere with Early Complications in Renal Transplantation. Anal Cell Pathol (Amst). 2019 Mar 25;2019:8389765. doi: 10.1155/2019/8389765. eCollection 2019. PubMed PMID: 31019876. PubMed CentralPMCID: PMC6452532. See more on PubMed
  • Ishikawa C, Jomori T, Tanaka J, Senba M, Mori N. Peridinin, a carotenoid, inhibits proliferation and survival of HTLV-1-infected T-cell lines. Int J Oncol. 2016 Oct;49(4):1713-21. doi: 10.3892/ijo.2016.3648. Epub 2016 Aug 4. PubMed PMID: 27499015. See more on PubMed
  • Ishikawa C, Senba M, Mori N. Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma. Oncol Lett. 2016 Jul;12(1):387-392. doi: 10.3892/ol.2016.4624. Epub 2016 May 25. PubMed PMID: 27347156. PubMed CentralPMCID: PMC4907013. See more on PubMed
Summary References (18)

References to CD30

  • Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994 Apr 29;264 (5159):667-8
  • Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol. 1995 May-Jun;13 (3):339-43
  • Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G, Almerigogna F, De Carli M, Pizzolo G. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol. 1996 Feb;26 (2):329-34
  • Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature. 1994 Feb 3;367 (6462):425-8
  • Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992 Feb 7;68 (3):421-7
  • Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85 (1):1-14
  • Farrah T, Smith CA. Emerging cytokine family. Nature. 1992 Jul 2;358 (6381):26
  • Fattovich G, Vinante F, Giustina G, Morosato L, Alberti A, Ruol A, Pizzolo G. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol. 1996 Jan;103 (1):105-10
  • Fonatsch C, Latza U, Durkop H, Rieder H, Stein H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics. 1992 Nov;14 (3):825-6
  • Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting R, Hansen H, Stein H. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol. 1987 Sep 15;139 (6):2081-7
  • Gerli R, Muscat C, Bistoni O, Falini B, Tomassini C, Agea E, Tognellini R, Biagini P, Bertotto A. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol. 1995 Dec;102 (3):547-50
  • Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994 Apr 15;83 (8):2045-56
  • Hansen HP, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer. 1995 Nov 27;63 (5):750-6
  • Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989 Jan;19 (1):157-62
  • Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol. 1996 Sep;80 (3 Pt 1):311-20
  • Latza U, Foss HD, Durkop H, Eitelbach F, Dieckmann KP, Loy V, Unger M, Pizzolo G, Stein H. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol. 1995 Feb;146 (2):463-71
  • Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol. 1994 Apr;12 (4):793-7
  • Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, et al. Serum levels of s
Related Products Docs